MIN Stock Overview
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Synlogic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$14.25 |
| 52 Week Low | US$3.33 |
| Beta | 1.16 |
| 1 Month Change | 0% |
| 3 Month Change | -92.91% |
| 1 Year Change | -97.17% |
| 3 Year Change | -98.99% |
| 5 Year Change | -99.72% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | -97.2% | -19.4% | -0.4% |
Return vs Industry: MIN underperformed the German Biotechs industry which returned -22.1% over the past year.
Return vs Market: MIN underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| MIN volatility | |
|---|---|
| MIN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MIN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MIN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 72 | Aoife Brennan | www.synlogictx.com |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma.
Synlogic, Inc. Fundamentals Summary
| MIN fundamental statistics | |
|---|---|
| Market cap | €30.38m |
| Earnings (TTM) | -€53.99m |
| Revenue (TTM) | €643.08k |
47.2x
P/S Ratio-0.6x
P/E RatioIs MIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIN income statement (TTM) | |
|---|---|
| Revenue | US$708.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$708.00k |
| Other Expenses | US$60.15m |
| Earnings | -US$59.44m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,396.05% |
| Debt/Equity Ratio | 0% |
How did MIN perform over the long term?
See historical performance and comparison